See All Slides - tctmd.com

Slides

Presentation ACC 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presenter: James L. Januzzi Jr

April 08, 2024

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

Presentation ACC 2024

Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial

Presenter: Alexander Fanaroff

April 07, 2024

Presentation ACC 2024

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

April 07, 2024

Presentation ACC 2024

PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer and lymphoma?

Presenter: David Austin

April 08, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

Presentation ACC 2024

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Presenter: Gervasio A. Lamas

April 07, 2024

Presentation ACC 2024

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Presenter: C. Michael Gibson

April 06, 2024

Presentation ACC 2024

Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial

Presenter: Javed Butler

April 06, 2024

Presentation ACC 2024

Principal Results from the RELIEVE-HF Trial

Presenter: Gregg W. Stone

April 06, 2024

Advertisement

Slides

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer and lymphoma?

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Empagliflozin after Acute Myocardial Infarction: The EMPACT-MI trial

Principal Results from the RELIEVE-HF Trial

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content